fda warns hims & hers for selling unapproved compounded semaglutide and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What's Next? FDA Ban on Compounded GLP-1

Since FDA declared the semaglutide shortage resolved on February 21, 2025, ended its enforcement-discretion windows in spring 2025, and then announced new action against mass-marketed non-FDA-approved GLP-1 drugs on February 6, 2026, GLP-1 telehealth startup compliance now depends on whether you are still facilitating compounded supply or enabling noncompliant GLP-1 prescribing workflows

SURMOUNT trial data showed tirzepatide patients achieving triglyceride reductions of up to 24% and HDL increases of up to 8% at the highest doses

[100] investigated the relationship between intestinal flora and obesity

Additionally, the proportion of phagocytosing PBMC, as well as their phagocytic capacity, increased after the LPS injection (11)